Rapport Therapeutics (RAPP) Competitors $14.94 -0.66 (-4.23%) Closing price 04:00 PM EasternExtended Trading$14.95 +0.01 (+0.07%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RAPP vs. AGIO, DNLI, IDYA, TARS, IRON, HRMY, MESO, CGON, ADPT, and VCELShould you be buying Rapport Therapeutics stock or one of its competitors? The main competitors of Rapport Therapeutics include Agios Pharmaceuticals (AGIO), Denali Therapeutics (DNLI), IDEAYA Biosciences (IDYA), Tarsus Pharmaceuticals (TARS), Disc Medicine (IRON), Harmony Biosciences (HRMY), Mesoblast (MESO), CG Oncology (CGON), Adaptive Biotechnologies (ADPT), and Vericel (VCEL). These companies are all part of the "pharmaceutical products" industry. Rapport Therapeutics vs. Its Competitors Agios Pharmaceuticals Denali Therapeutics IDEAYA Biosciences Tarsus Pharmaceuticals Disc Medicine Harmony Biosciences Mesoblast CG Oncology Adaptive Biotechnologies Vericel Agios Pharmaceuticals (NASDAQ:AGIO) and Rapport Therapeutics (NASDAQ:RAPP) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations. Is AGIO or RAPP more profitable? Agios Pharmaceuticals has a net margin of 1,590.42% compared to Rapport Therapeutics' net margin of 0.00%. Agios Pharmaceuticals' return on equity of -3.49% beat Rapport Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Agios Pharmaceuticals1,590.42% -3.49% -3.23% Rapport Therapeutics N/A -29.99%-28.64% Which has higher valuation and earnings, AGIO or RAPP? Agios Pharmaceuticals has higher revenue and earnings than Rapport Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAgios Pharmaceuticals$40.88M52.14$673.72M$11.003.33Rapport TherapeuticsN/AN/A-$78.31M-$2.50-5.98 Does the media refer more to AGIO or RAPP? In the previous week, Rapport Therapeutics had 4 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 12 mentions for Rapport Therapeutics and 8 mentions for Agios Pharmaceuticals. Agios Pharmaceuticals' average media sentiment score of 0.93 beat Rapport Therapeutics' score of 0.57 indicating that Agios Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rapport Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer AGIO or RAPP? Agios Pharmaceuticals currently has a consensus price target of $56.33, suggesting a potential upside of 53.58%. Rapport Therapeutics has a consensus price target of $29.50, suggesting a potential upside of 97.46%. Given Rapport Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Rapport Therapeutics is more favorable than Agios Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agios Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75Rapport Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, AGIO or RAPP? Agios Pharmaceuticals has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Rapport Therapeutics has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. SummaryAgios Pharmaceuticals beats Rapport Therapeutics on 10 of the 13 factors compared between the two stocks. Get Rapport Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RAPP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RAPP vs. The Competition Export to ExcelMetricRapport TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$545.28M$3.08B$5.58B$9.81BDividend YieldN/A2.27%4.60%4.11%P/E Ratio-5.9820.5630.2825.72Price / SalesN/A191.86388.3180.18Price / CashN/A42.0537.7558.93Price / Book2.077.598.456.01Net Income-$78.31M-$54.65M$3.25B$265.06M7 Day Performance-3.05%5.43%4.05%2.80%1 Month Performance2.12%6.75%4.32%1.68%1 Year Performance-26.76%31.59%36.25%29.59% Rapport Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAPPRapport Therapeutics1.7686 of 5 stars$14.94-4.2%$29.50+97.5%-23.4%$545.28MN/A-5.98N/AEarnings ReportAnalyst RevisionAGIOAgios Pharmaceuticals4.3832 of 5 stars$35.10-1.8%$56.33+60.5%-18.8%$2.08B$36.50M3.19390Insider TradeDNLIDenali Therapeutics4.1757 of 5 stars$13.91-0.3%$33.85+143.3%-35.7%$2.03B$330.53M-5.21430News CoverageEarnings ReportAnalyst RevisionGap DownIDYAIDEAYA Biosciences4.4441 of 5 stars$22.84-1.1%$48.09+110.6%-36.0%$2.02B$7M-6.0380Analyst RevisionTARSTarsus Pharmaceuticals1.7622 of 5 stars$50.07+4.6%$66.67+33.1%+99.4%$2.02B$182.95M-21.4950Insider TradeAnalyst RevisionIRONDisc Medicine3.2375 of 5 stars$58.59+1.0%$95.73+63.4%+33.2%$2.01BN/A-13.1130Earnings ReportHRMYHarmony Biosciences4.5691 of 5 stars$34.80+1.8%$51.00+46.6%+4.5%$1.97B$714.73M11.23200Analyst RevisionMESOMesoblast2.4409 of 5 stars$14.70-2.2%$18.00+22.4%+140.7%$1.92B$5.90M0.0080Gap UpCGONCG Oncology1.4757 of 5 stars$23.94-3.7%$55.30+131.0%-20.9%$1.89B$1.14M-13.5361Earnings ReportAnalyst RevisionADPTAdaptive Biotechnologies2.8015 of 5 stars$12.15-0.4%$12.38+1.9%+185.1%$1.86B$178.96M-14.82790Gap DownVCELVericel2.4494 of 5 stars$35.43-2.2%$60.33+70.3%-17.5%$1.83B$237.22M295.27300Positive News Related Companies and Tools Related Companies AGIO Competitors DNLI Competitors IDYA Competitors TARS Competitors IRON Competitors HRMY Competitors MESO Competitors CGON Competitors ADPT Competitors VCEL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RAPP) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredYour blueprint for crypto wealthYou only need to be right once in crypto (here's how) Don't miss this opportunity to arm yourself with know...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapport Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapport Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access